There is an undeniable cycle to nature. Leaves turn color and fall, birds migrate across continents, and stocks fall after the annual American Society of Clinical Oncology (ASCO) meeting. Making matters perhaps a bit worse this year, there were very few presentations that really stood out and not an abundance of positive news for investors to process. As is so often the case, though, there was a lot of buying momentum into the meeting and Wall Street is once again playing out the "buy the rumor, sell the news" meme.

Tutorial: The Industry Handbook

The Best in Show - YMI and Exelixis
The most interesting presentations arguably belonged to YM BioSciences (AMEX:YMI) and Exelixis (Nasdaq:EXEL). It is also par for the course, though, that neither presentation was completely "clean" and investors still have a lot of questions about the future of the respective drugs.

For YMI, it was all about Phase 1/2 data from the JAK-2 inhibitor CYT387 in myelofibrosis. Myelofibrosis is a rare condition and one that frequently leads to an enlarged spleen and/or anemia. This relatively small study showed good spleen response and suggested benefit in counteracting anemia. Unfortunately, this is the prime question about CYT387 - is the anemia benefit "real"? If so, this could be a drug worth hundreds of millions of dollars, but investors are just going to have to wait for further studies to confirm (or disprove) this benefit. On an encouraging note, the company seems to be taking a very smart approach to the clinical development of the drug. (For more, see Measuring The Medicine Makers.)

For Exelixis, the real excitement was about Phase 2 data for cabozantinib in seriously ill prostate cancer patients. The trial showed a meaningful reduction in tumor progression, and bone scans showed that 76% of the patients were partially or completely cleared of bone lesions. The drug also seemed to have a very significant benefit to reducing pain (metastasis of prostate cancer into the bone is excruciating). (For more, see Drug Companies With Tasty Medicine.)

Now the bad news. There have been deaths associated with this drug (1 tied to the drug in the prostate study) and it seems like the mechanism of action makes that almost inevitable. Also, the company has not designed the studies to show survival benefit, and it could be challenging to secure FDA approval without that data - particularly as Bristol-Myers (NYSE:BMY) showed data at ASCO from its Phase 3 prostate drug candidate (alpharadin - licensed from Algeta) that did point to a survival benefit.

Controversy Still Swirling Around Neoprobe
Neoprobe (Nasdaq:NEOP) is a pretty small company, but the controversy around the stock and its drug Lymphoseek is large indeed. Lymphoseek is actually an imaging agent, but the approval process is essentially identical as if it were a drug. The good news is that Lymphoseek did exceed the endpoints of its Phase 3 study and seems to be a highly sensitive agent. It also would seem to have non-trivial safety benefits and an improved administration profile over the standard of care.

Unfortunately, there is controversy about whether the company has run the proper trials. The trials have compared Lymphoseek to an FDA-approved alternative when the actual standard of care is to use a combination of that approved alternative (vital blue dye) and a colloid. The question, then, is whether Neoprobe can establish superior efficacy in a real world setting, though the safety profile may mitigate that argument. It's also worth noting that while Lymphoseek would certainly be significant to Neoprobe, the list of breakaway biotech successes based on imaging compounds is pretty sparse. (For more, see A Primer On The Biotech Sector.)

Other Data of Note
Bristol-Myers also reported very encouraging data on Yervoy (ipilimumab) in skin cancer; so much so that it could dominate the "wild type BRAF" melanoma market. Incyte (Nasdaq:INCY) and partner Novartis (NYSE:NVS) reported strong data on their myelofibrosis drug ruxolitinib. In contrast to YMI's drug, there is very good spleen response with ruxolitinib, but not much anemia benefit. Nevertheless, this drug is years ahead of YMI's compound and the two companies have filed for U.S. approval.

Other reports of some note include data from Celgene (Nasdaq:CELG) that was supportive of Revlimid but negative for Abraxane (showing a better response rate than paclitaxel, but no survival benefit in lung cancer) and solid data from Sanofi's (NYSE:SNY) semuloparin, an ultra-low weight heparin targeted at preventing venous clots in cancer patients. (For more, see Pharmaceutical Phenoms: America's Best-Selling Medicines.)

The Bottom Line
Many biotech investors seemed puzzled by Monday's post-ASCO declines, but they should take some solace in the fact that this is a very routine occurrence. While there are still a lot of questions for investors in stocks like YMI, Exelixis, and Neoprobe, bulls can certainly find some positive news to reinforce their thesis. As always, the key to successful biotech investing is diversification, staying power and due diligence. (For more, see The Ups And Downs Of Biotechnology.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing

    Asset Manager Ethics: Acting With Competence and Diligence

    Managers must make investment decisions based on their personal investment process, which in turn should be based on solid research and due diligence.
  2. Forex Education

    Understanding The Income Statement

    Learn how to use revenue and expenses, among other factors, to break down and analyze a company.
  3. Stock Analysis

    Will J.C. Penney Come Back in 2016? (JCP)

    J.C. Penney is without a doubt turning itself around, but that doesn't guarantee the stock will respond immediately.
  4. Investing

    Time to Bring Active Back into a Portfolio?

    While stocks have rallied since the economic recovery in 2009, many active portfolio managers have struggled to deliver investor returns in excess.
  5. Economics

    Investing Opportunities as Central Banks Diverge

    After the Paris attacks investors are focusing on central bank policy and its potential for divergence: tightened by the Fed while the ECB pursues easing.
  6. Stock Analysis

    The Biggest Risks of Investing in Pfizer Stock

    Learn the biggest potential risks that may affect the price of Pfizer's stock, complete with a fundamental analysis and review of other external factors.
  7. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  8. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  9. Markets

    PEG Ratio Nails Down Value Stocks

    Learn how this simple calculation can help you determine a stock's earnings potential.
  10. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  1. What does low working capital say about a company's financial prospects?

    When a company has low working capital, it can mean one of two things. In most cases, low working capital means the business ... Read Full Answer >>
  2. Do nonprofit organizations have working capital?

    Nonprofit organizations continuously face debate over how much money they bring in that is kept in reserve. These financial ... Read Full Answer >>
  3. Can a company's working capital turnover ratio be negative?

    A company's working capital turnover ratio can be negative when a company's current liabilities exceed its current assets. ... Read Full Answer >>
  4. Does working capital measure liquidity?

    Working capital is a commonly used metric, not only for a company’s liquidity but also for its operational efficiency and ... Read Full Answer >>
  5. How do I read and analyze an income statement?

    The income statement, also known as the profit and loss (P&L) statement, is the financial statement that depicts the ... Read Full Answer >>
  6. Can working capital be too high?

    A company's working capital ratio can be too high in the sense that an excessively high ratio is generally considered an ... Read Full Answer >>

You May Also Like

Trading Center